Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | DRD4 | P21917 | 3/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.72 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.72 |
| ▸ | HRH1 | P35367 | 1/20 | 0.72 |
| ▸ | DRD3 | P35462 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500534 | 0.86 | DRD2 (0.67) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL4500671 | 0.86 | DRD2 (0.67) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL4486407 | 0.85 | CHRM1 (0.65) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL4504985 | 0.85 | DRD2 (0.65) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL4508385 | 0.84 | CHRM1 (0.58) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL4501097 | 0.84 | DRD2 (0.71) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL4504348 | 0.84 | DRD2 (1.00) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL4490224 | 0.84 | DRD2 (0.65) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL31060842 | 0.84 | DRD2 (1.00) | DRD2CHRM1DRD4ADRA1ACHRM2 | |
| SCHEMBL4510530 | 0.84 | CHRM1 (0.71) | DRD2CHRM1DRD4ADRA1ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485651-B2 | Compounds with activity on muscarinic receptors | ACADIA PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | BRANN MARK | 2008-05-08 | — | — | US | disclosed |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | BRANN MARK (US) | 2003-07-31 | — | — | US | disclosed |
| US-6528529-B1 | 4-Methoxy-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine | ACADIA PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1068185-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050247-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | ACADIA PHARMACEUTICALS, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108618-A1 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS | CHRM3, CHRM2, CHRM1 | DRD2 470/4885CHRM1 3/4885DRD4 824/4885 |
| US-20030144285-A1 | Compounds with activity on muscarinic receptors | CHRM3, CHRM2, CHRM1 | DRD2 470/4885CHRM1 3/4885DRD4 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.